Creo Medical Group PLC 73.7% potential upside indicated by Numis

Creo Medical Group PLC with ticker (LON:CREO) now has a potential upside of 73.7% according to Numis.



Numis set a target price of 100 GBX for the company, which when compared to the Creo Medical Group PLC share price of 26 GBX at opening today (23/03/2023) indicates a potential upside of 73.7%. Trading has ranged between 18 (52 week low) and 115 (52 week high) with an average of 1,353,957 shares exchanging hands daily. The market capitalisation at the time of writing is £91,231,712.

Creo Medical Group plc is engaged in the research and development and the manufacture and sale of medical devices and instruments. The Company is focused on the research, development, and distribution of electrosurgical medical devices relating to the field of surgical endoscopy. It has four technology families, which include Speedboat, SpydrBlade, MicroBlate, and SlypSeal. Speedboat is its flagship advanced energy device product with over 1,000 procedures performed using the device. Speedboat device technology is a device technology with bipolar surgical dissection blade in any form of surgery. Additionally, Speedboat integrates microwave technology allowing for precise control of bleeding during surgery. The Company’s SpydrBlade device technology optimizes the power of its CROMA Platform, where advanced bipolar radiofrequency (RF) energy is used to cut tissue and precisely controlled microwave energy is used for the coagulation and sealing of tissue during surgery.